L-serine for GRIN-related neurodevelopmental disorders
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether an amino acid supplement called L-serine can help people with GRIN-related neurodevelopmental disorders. These disorders are caused by specific genetic changes that affect brain function, and the study aims to see if L-serine can improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a GRIN-related neurodevelopmental disorder (caused by a change in the GRIN1, GRIN2A, GRIN2B, or GRIN2D genes).
- Genetic testing must show a specific type of gene change (loss-of-function) that stops the gene from working properly.
- You must be at least 2 years old at the time of screening.
- If you have taken L-serine before, you must be willing to stop taking it for at least one week before the study starts.
- You must not have any serious unstable medical condition (other than epilepsy) or other diseases that could interfere with the study.
- You must not be pregnant or breastfeeding, and cannot have participated in another drug trial in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with SLC13A5 deficiency (a rare genetic condition that affects brain development) to learn more about the disease over time. It collects health information, assessments, and samples to help understand the condition and plan future treatments.
This trial tests whether taking lithium for 2 years can improve symptoms in people with a TBR1 gene change that causes neurodevelopmental challenges. It aims to see if lithium is safe and helpful for this condition.
This study uses a newer, more detailed type of genetic testing (long-read genome sequencing) to look for the cause of severe childhood epilepsy and developmental delays when standard testing has found nothing. The goal is to find answers for families who have gone without a diagnosis.
This trial tests a new drug for children with GRIN-related neurodevelopmental disorder caused by certain gene changes. The drug aims to improve seizures and other symptoms.
This study tests a drug called phenylbutyrate for people with seizures caused by SLC6A1 gene changes. The drug may help reduce seizure frequency. The trial is fully remote, so you can join from anywhere in the U.S. without going to a clinic.
This trial studies whether a supplement called glycine (an amino acid) can help improve fatty liver disease. It involves taking the supplement daily and doing MRI scans to see if the fat in your liver changes.
Hear when a new Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.